Clinical Trials Logo

Autoimmune Pancreatitis clinical trials

View clinical trials related to Autoimmune Pancreatitis.

Filter by:

NCT ID: NCT06468709 Recruiting - Type 1 AIP Clinical Trials

A Trial on the Recurrence Free Survival Rate of Type I AIP With High-risk of Recurrence

Start date: June 20, 2024
Phase: Phase 4
Study type: Interventional

Autoimmune pancreatitis (AIP) is an autoimmune disease with low incidence rate and involving the pancreas. In China, type I AIP is predominant. Glucocorticoids (GC) have a significant therapeutic effect. Even though a consensus has been reached on the effective initial GC treatment dose, type I AIP is prone to recurrence after GC induction and maintenance therapy. Currently, there is no consensus on how to reduce the disease recurrence rate in high-risk type I AIP patients. Multiple studies have shown that immunosuppressants (IM) combined with GC can effectively reduce the disease recurrence rate in IgG4 RD patients, including azathioprine, mycophenolate mofetil (MMF), etc. Among them, the incidence of adverse reactions in MMF is relatively low. As a special type of IgG4-RD, there is currently no prospective study evaluating the efficacy and safety of GC combined with MMF treatment in high-risk recurrent type I AIP patients. The smooth implementation of this project can provide new treatment ideas and evidence-based medicine for reducing the recurrence rate of high-risk type I AIP.

NCT ID: NCT06369909 Recruiting - Clinical trials for Autoimmune Pancreatitis

Study on AI-assisted Multimodal Diagnosis System of Autoimmune Pancreatitis

Start date: January 31, 2024
Phase:
Study type: Observational [Patient Registry]

The existing comprehensive diagnostic system for autoimmune pancreatitis (AIP) is complex, with multidimensional clinical information including morphological changes and a lack of specific biomarkers. Endoscopic ultrasound (EUS) can provide all the elements for morphological diagnosis of AIP, but the long learning curve and large observer differences make it difficult to popularize and promote. The cooperation units of the three regions in this project have found in the early stage that Klebsiella pneumoniae (KP) induced follicular helper T cells (Tfh) activation is an important mechanism of AIP, but the identification of pathogenic components of the strain and clinical validation need to be explored. We have established a national multicenter AIP queue in the early stage and extracted EUS audio-visual features to establish a scoring model, but intelligent assistance is still needed to improve efficiency. Therefore, we plan to integrate gut microbiota, Tfh activation markers, and EUS imaging features to establish an AI assisted multimodal diagnostic system for AIP. This study will collaborate across multiple centers to identify and validate the components that induce Tfh activation in KP bacterial cells, to extract EUS pancreatic ultrasound features and optimize artificial intelligence assisted diagnostic algorithms, and to establish and validate an artificial intelligence assisted multimodal diagnostic system based on clinical information, biomarkers, and EUS. The aim of this study is to provide new diagnosis and treatment evaluation methods for AIP with high accuracy, convenience, and easy promotion for clinical practice.

NCT ID: NCT06358001 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

EchoTip AcuCore Post-Market Clinical Study

Start date: June 1, 2024
Phase:
Study type: Observational

The purpose of collecting this data is to continue to learn more about the EchoTip AcuCore and the device's ability to produce the desired favorable effect and if there are any undesired outcomes that may be related to the EchoTip AcuCore.

NCT ID: NCT06328101 Not yet recruiting - Clinical trials for Autoimmune Pancreatitis Type 2

Autoimmune Pancreatitis, Pancreatic and Extrapancreatic cAnceR (AiPPEAR)

AiPPEAR
Start date: May 1, 2024
Phase:
Study type: Observational

The goal of this observational, retrospective study is to learn about cancer risk in autoimmune pancreatitis (AIP) patients. The main questions it aims to answer are: - Do patients with AIP have higher incidence of cancer in comparison to general population? - What is the overall prevalence of cancer in AIP patients? - What are the characteristics of AIP patients associated with the incidence of cancer?

NCT ID: NCT05565066 Completed - Clinical trials for Neuroendocrine Tumors

A Real-world Comparison of FNB and FNA in IHC-required Lesions.

Start date: December 1, 2014
Phase:
Study type: Observational

Endoscopic ultrasound (EUS)-guided fine needles with side fenestrations are used to collect aspirates for cytology analysis and biopsy samples for histologic analysis. The investigators conducted a large, multicenter study to compare the accuracy of diagnosis via specimens collected with fine-needle biopsy (FNB) versus fine-needle aspiration (FNA) for patients with lesions requiring immunohistochemistry (IHC) pathological diagnosis.

NCT ID: NCT05476978 Completed - Clinical trials for Pancreatic Ductal Adenocarcinoma

Artificial Intelligence in EUS for Diagnosing Pancreatic Solid Lesions

Start date: July 1, 2022
Phase:
Study type: Observational

We aim to develop an EUS-AI model which can facilitate clinical diagnosis by analyzing EUS pictures and clinical parameters of patients.

NCT ID: NCT05171517 Completed - Clinical trials for Pancreatic Carcinoma

Study on Microflora Characteristics of Pancreatic Solid Lesions Via Endoscopic Ultrasound-guided Fine Needle Aspiration/Biopsy

Start date: January 1, 2022
Phase:
Study type: Observational

Study objective: To describe the microflora characteristics of the pancreatic solid lesions via the tissue acquired via the endoscopic ultrasound-guided fine needle aspiration/biopsy (EUS-FNA/B). Study design: This is a prospective observational study.

NCT ID: NCT05095831 Active, not recruiting - Pancreatitis Clinical Trials

EUS Shear Wave for Solid Pancreatic Lesions.

Start date: October 1, 2021
Phase:
Study type: Observational [Patient Registry]

The diagnosis of pancreas diseases is based on a combination of clinical signs, symptoms, and laboratory tests, but mainly on imaging techniques such as computed tomography (CT) and magnetic resonance (MR). However, CT/MR have variable sensitivity and specificity, with certain disadvantages. Endoscopic ultrasound with elastography is an important resource with higher diagnostic accuracy in assessing solid pancreas lesions. Shear wave velocities of healthy parenchyma, acute, chronic and autoimmune pancreatitis, neoplastic lesions of the pancreas must be evaluated and compared.

NCT ID: NCT04834505 Recruiting - Pancreatic Cancer Clinical Trials

To Differentiate Focal Autoimmune Pancreatitis From Pancreatic Cancer by Endoscopic Ultrasound

Start date: May 11, 2021
Phase:
Study type: Observational

Autoimmune pancreatitis (AIP) is a special type of chronic pancreatitis mediated by autoimmunity. The classic manifestation of AIP is diffuse pancreatic enlargement, some of which are characterized by focal enlargement. Clinically, it is divided into diffuse AIP (DAIP) and focal AIP (FAIP) according to morphology. FAIP can be clinically manifested as obstructive jaundice, peripancreatic lymphadenopathy and vascular involvement, which may mimic pancreatic cancer (PC). CT/MRI is the important imaging tool for diagnosing pancreatic diseases. However, due to the overlap of the imaging features of FAIP and PC, it is challenging to differentiate the two by CT/MRI. Endoscopic ultrasound (EUS) can clearly display the pancreatic parenchyma and pancreatic duct system and has become a routine modality for the evaluation of pancreatic diseases. The aim of this study is to construct a diagnosis model for distinguishing between FAIP and PC by comparing the EUS characteristics of the two, and further validate its diagnostic efficacy.

NCT ID: NCT04397731 Recruiting - Clinical trials for Autoimmune Pancreatitis

Prospective Study on the Role of Eus-fnb in the Diagnosis of Autoimmune Pancreatitis

BIO_AIP
Start date: May 1, 2020
Phase:
Study type: Observational [Patient Registry]

According to the reported histological procurement yield of the end-cutting needles, the investigators supposed that the use of EUS-FNB in probable AIP patients, generally aimed only to rule-out malignancy, could provide histological tissue samples useful in enhancing the diagnostic level reached without histology, or defining the type of AIP.